STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) usually originates from the precancerous lesions of oral mucosa and accounts for approximately 90% of oral cancers. Current therapeutic approaches do not yet meet the needs of patients, and the 5-year survival rate of patients with OSCC is only 50%. Recent studies...
Main Authors: | Mingjing Jiang, Bo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/19/3131 |
Similar Items
-
Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression
by: Levi Arnold, et al.
Published: (2023-10-01) -
STAT1 inhibits STAT3 activation in esophageal squamous cell carcinoma
by: Liu Z, et al.
Published: (2018-11-01) -
Small Molecules in the Treatment of Squamous Cell Carcinomas: Focus on Indirubins
by: Mirijam Schäfer, et al.
Published: (2021-04-01) -
CircPUM1 Knockdown Confers Radiosensitivity in Oral Squamous Cell Carcinoma by Regulating the miR-580/STAT3 Pathway
by: Linghui Jia, et al.
Published: (2022-08-01) -
The oncogenic role of NOTCH1 as biomarker in oral squamous cell carcinoma and oral lichen planus
by: Ensieh Sagheb Sadeghi, et al.
Published: (2023-01-01)